Thymosin Alpha-1
Also known as: Tα1, Zadaxin, Thymalfasin
Thymosin alpha 1 is an immune-modulating thymic peptide. Published reviews describe effects on T-cell, dendritic-cell, natural-killer-cell, cytokine, and innate immune signaling, so ProtoComp should present it as immune-context data rather than as direct workout or nutrition leverage.
- Thymosin alpha 1: A comprehensive review of the literature.
World journal of virology · 2020 · PMID 33362999
Approved in 30+ countries (not US) as Zadaxin for hepatitis B, used adjunctively for hepatitis C and as an oncology adjunct. Twice-weekly dosing is standard.
Hepatitis protocols run 6 months. Shorter cycles used for immune support.
No specific timing — consistency matters more than hour of day.
Contraindications
- • Organ transplant recipients on immunosuppression
Common side effects
- • Injection site reactions
- • Transient erythema
Serious risks
- • Theoretical risk of worsening autoimmune conditions
Drug interactions
- • May reduce efficacy of immunosuppressants
Requires monitoring
- • Complete blood count if long-term use
Pregnancy / breastfeeding
Not recommended — limited safety data in pregnancy
- Not a stimulant or energy peptide — modulates immune function over weeks
- Discuss with clinician if using with any immunomodulating therapy
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.